Moloney murine leukemia virus (M-MuLV) is a simple nonacute retrovirus that induces T-lymphoblastic lymphoma in NIH Swiss mice. A frequent event during the development of MuLV-induced leukemias is the formation of mink cell focusinducing (MCF) recombinant viruses (18) . MCF viruses arise by recombination in vivo between the env gene of an infecting MuLV and endogenous polytropic or modified polytropic MuLV proviruses present in virtually all mice (33) . MCF envelope protein binds to cells via a different receptor from that used by the original ecotropic MuLVs (25) . Several lines of evidence suggest that MCF recombinants play important roles in MuLV-induced leukemogenesis in mice, but the exact role(s) remains unclear (15) . For example, MCF recombinants may carry out late functions, including long terminal repeat (LTR) activation of proto-oncogenes (19) , activation of cytokine receptors (21) , and additional rounds of superinfection of cells already infected with ecotropic MuLV (20) .
MCF recombinants may also be important early during leukemogenesis by M-MuLV, as suggested by comparative studies of M-MuLV and an enhancer variant of M-MuLV, MoϩPyF101 M-MuLV (15) . MoϩPyF101 M-MuLV contains enhancer sequences from the F101 strain of polyomavirus inserted downstream from the M-MuLV enhancers (23) . Leukemogenicity of MoϩPyF101 M-MuLV is dependent on the route of inoculation: MoϩPyF101 M-MuLV inoculated subcutaneously (s.c.) is poorly leukemogenic, while MoϩPyF101 M-MuLV inoculated intraperitoneally (i.p.) results in disease kinetics comparable to those induced by wild-type M-MuLV (1, 6, 10) . In contrast, M-MuLV induces leukemia efficiently with the same kinetics regardless of the route of inoculation (1) . Experiments with MoϩPyF101 M-MuLV indicated that early high-level infection of the thymus (the ultimate site of tumor formation) apparently was not required for efficient disease induction by M-MuLV. Instead, efficient disease induction was correlated with efficient early infection of the bone marrow and the appearance of MCF recombinants (1, 2) . Since early bone marrow infection was well correlated with the development of MCF recombinants, this suggested that infection of bone marrow might be required for recombinant MCF virus formation. The association also suggested that MCF recombinant formation and/or initial propagation may take place in the bone marrow. In addition, studies with MoϩPyF101 M-MuLV suggested that MCF recombinants might be involved in the establishment of preleukemic changes such as generalized hematopoietic hyperplasia in the spleen, defects in bone marrow hematopoiesis, and accelerated thymic atrophy (11, 12, 22) .
The goals of this study were to characterize the initial sites of MCF recombinant appearance in mice following M-MuLV M-MuLV that is reactive with both ecotropic M-MuLV and polytropic M-MCF recombinants (4) . Random primer [ 32 P]dATP-(or [ 32 P]dCTP)-labeled probes were prepared by using the DECAprime II DNA labeling kit (Ambion, Austin, Tex.) as specified by the manufacturer. When indicated, the probes were stripped from the membranes by incubation at 95 to 100°C in 0.1ϫ SSC (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate)-1% sodium dodecyl sulfate for 40 to 60 min with gentle agitation and the membranes were rehybridized as described above.
RESULTS
MCF recombinant appearance and propagation in M-MuLV i.p.-inoculated mice. The site(s) of MCF recombinant generation during M-MuLV infection is unknown. Our previous studies suggested that the bone marrow might be involved in MCF virus formation or propagation (2, 6) , but other candidate hematopoietic compartments included the spleen and thymus. High levels of ecotropic virus infection are established in all three tissue compartments at early times postinfection (Ͻ14 days) (1), and MCF recombinants have been detected in the spleen and thymus of M-MuLV-infected mice as early as 3-4 weeks, although the bone marrow was not examined (14, 20) . Our initial strategy to identify the site(s) of MCF recombinant generation was to search different tissues for the earliest appearance of MCF recombinants.
Immediately after MCF recombinant formation and initial propagation, it is likely that only a small fraction of cells will express MCF virus. However, at later times, MCF recombinants will have amplified in vivo by several orders of magnitude. We evaluated the sensitivity, range of detection, and reproducibility of several different methods of MCF recombinant detection including Southern blot hybridization (32), PCR amplification (24, 27, 28) , and IC assays (FIAs) (31) . FIA proved to be the most sensitive and reliable technique, allowing measurements of MCF virus ICs over a range of 6 to 7 orders of magnitude (0.00002 to 100% of cells infected). Another advantage of the FIA was that it measured infectious MCF recombinants.
We infected neonatal mice i.p. with M-MuLV and quantified the appearance of MCF virus-infected cells in the bone marrow, spleens, and thymuses of infected mice during the preleukemic period by measuring MAb 514-reactive ICs by FIA of cells from these hematopoietic compartments. MAb 514 is specifically reactive with the SU proteins of polytropic (and modified polytropic) MuLVs, including the two antigenic subclasses of recombinant MCFs that appear during M-MuLV infection (7, 13) . We also measured the appearance of ecotropic M-MuLV-infected cells in the same tissues by FIA with MAb 538. MAb 538 is specifically reactive with the ecotropic SU protein of M-MuLV. As shown in Fig. 1A , mice inoculated i.p. with M-MuLV showed a rapid appearance of ecotropic ICs in the bone marrow, spleen, and thymus. The appearance of M-MuLV ecotropic ICs in the thymus was slightly delayed compared to that in bone marrow and spleen: maximum numbers of ecotropic ICs were detected in the bone marrow and spleen by 7 to 10 days, in contrast to 13 to 15 days for the thymus. At later times, the numbers of ecotropic ICs in the thymus were somewhat higher (approximately 5-to 10-fold) than in the bone marrow and spleen. These results were consistent with previous reports on M-MuLV-infected mice (1, 14) . hematopoietic compartments in all animals. Thus, they had been generated and disseminated by that time. If MCF virus generation took place in only one tissue, propagation to the other two compartments occurred rapidly.
In mice infected i.p. with M-MuLV, the numbers of MCF virus ICs reached plateau levels by 4 to 5 weeks, most probably reflecting a rapid amplification of MCF virus infection between 3 and 5 weeks. It was noteworthy that the maximal numbers of polytropic ICs were substantially larger (10-to 100-fold) in the thymus than in the bone marrow and spleen. Thus, MCF recombinant amplification was most efficient in the thymus.
Sites of the earliest appearance of MCF recombinants following i.p. inoculation. The patterns of ecotropic and polytropic ICs shown in Fig. 1 did not readily suggest a site for MCF recombinant generation, since high-level ecotropic infection was established in all tissues before MCF recombinant ICs were detected in any of them. Furthermore, MCF recombinants were amplified in the bone marrow, spleen, and thymus with similar rapid kinetics. In most animals tested at 1 to 4 weeks, MCF recombinants were either absent from all three hematopoietic compartments or present in all of them. However, in a subset of animals, MCF recombinants were detected in one or two but not all three compartments. Thus, MCF recombinants apparently had not spread completely in these animals. The MCF recombinant IC profiles in these animals might suggest where MCF recombinant were generated. Table 1 summarizes the polytropic IC data from the animals that were "discordant" for detectable MCF recombinants, i.e., those that showed MCF recombinant ICs in at least one but not all tissues. MCF recombinant ICs were detected in the bone marrow in 14 of 15 discordant animals. In three animals, only the bone marrow sample showed detectable ICs. In contrast, only 4 of 15 discordant animals showed ICs in the spleen, although in 1 animal they were detected in only the spleen. An intermediate fraction of discordant animals (8 of 15) showed detectable ICs in the thymus; however, none of these 8 animals showed ICs only in the thymus. These findings were consistent with the possibility that the bone marrow was the primary site of MCF recombinant generation.
MCF recombinant appearance and propagation in M-MuLV s.c.-inoculated mice. Previous studies of wild-type and MoϩPyF101 M-MuLV indicated that the route of inoculation (i.p. versus s.c.) affected the efficiency of MoϩPyF101 M-MuLV-induced leukemogenesis but not that of M-MuLVinduced leukemogenesis (1) . Since leukemogenesis by M-MuLV is not dependent on the route of inoculation, studying MCF appearance in mice infected either i.p. or s.c. with M-MuLV might reveal common features important for efficient leukemogenesis.
We infected neonatal mice with M-MuLV s.c. and measured the appearance of polytropic and ecotropic reactive ICs. Relative to i.p. inoculation, s.c. inoculation resulted in a slight delay in establishment of ecotropic-virus infection in the bone marrow and spleen but had little effect on establishment of infection in the thymus ( Fig. 2A) . We first detected MCF ICs at 19 to 28 days postinoculation, 1 week later than for i.p.-inoculated mice ( later than when ecotropic M-MuLV IC numbers plateaued, and they amplified rapidly regardless of the inoculation route. The apparent 3-to 5-day delay in the appearance of MCF recombinants in the bone marrow with respect to the splenocytes and thymocytes of s.c.-inoculated mice suggested that they might form in some tissue other than bone marrow. Results for s.c.-inoculated animals discordant for MCF virus appearance are shown in Table 2 . MCF recombinant ICs were detected in the bone marrow in only two of eight discordant animals; furthermore, none of the discordant animals tested showed MCF recombinants only in bone marrow cells. Four of eight discordant animals showed detectable MCF recombinant ICs in the spleen, and none showed infection only in the spleen. In contrast, all eight discordant animals showed MCF recombinant ICs in the thymus and two of these animals showed MCF recombinant ICs only in the thymus. In mouse 8 (Table 2 ), a substantial number of MCF recombinant ICs was measured in the thymus but none were detected in the bone marrow or spleen. These results suggested that a site other than the bone marrow (perhaps the thymus) might function as an MCF recombinant generation site following s.c. inoculation. marrow and spleen, but the difference was not as great as in M-MuLV i.p.-inoculated mice. Figure 3B shows the appearance of MCF recombinant ICs in cells of MoϩPyF101 i.p.-infected mice. Polytropic ICs were first detected after 40 days on average (compared to 13 days for M-MuLV i.p.-infected mice), and the time of appearance was also more variable than that for M-MuLV-infected mice. In addition, not all animals showed MCF recombinant ICs: only two-thirds of the animals tested between 39 and 96 days postinoculation showed detectable MCF recombinant ICs, and only one-fourth of the animals at these times showed MCF recombinant ICs in all three tissues. Finally, MCF recombinant IC titers measured in the bone marrow and spleen were 100-to 1,000-fold lower than in M-MuLV i.p.-infected mice. Thus, either MCF virus generation occurred much later or propagation of MCF recombinants to detectable levels was less efficient. As in M-MuLV-infected animals, however, MCF recombinant amplification was most efficient in the thymus in MoϩPyF101 i.p.-infected mice (generally 100-fold higher levels than in the bone marrow and spleen). The delay in appearance of MCF recombinants was noteworthy, since previous experiments had suggested an early role for MCF recombinants in efficient leukemogenesis by MoϩPyF101 M-MuLV (2, 6, 22) .
MCF virus appearance in
We also studied animals discordant for MCF virus appearance following i.p. inoculation with MoϩPyF101 M-MuLV (Table 3) . Only one discordant animal showed detectable MCF recombinant ICs in bone marrow. MCF recombinant ICs were detected in the spleens in six of nine and in the thymuses in eight of nine discordant animals. In three mice, appreciable MCF recombinant IC numbers were detected only in the thymus.
MCF recombinant proviruses in Mo؉PyF101 M-MuLV i.p.-inoculated mice. The delay in appearance and the inefficient amplification of MCF recombinants in MoϩPyF101 M-MuLV i.p.-inoculated mice was unexpected from our previous experiments (2, 6) . Although unlikely, it was possible that MoϩPyF101 M-MuLV-infected mice developed significant FIG. 3 . Inoculation of MoϩPyF101 M-MuLV. Neonatal mice were inoculated i.p. with MoϩPyF101 M-MuLV, and the numbers of ecotropic and polytropic ICs were measured as described in the legend to Fig. 1 (solid triangles) . Data from mice inoculated s.c. by MoϩPyF101 M-MuLV are shown in shaded triangles. Note that the timescale in this figure is different than in Fig. 1 and 2 . Any animals that developed leukemia were excluded from the analysis. Fig. 4 , digestion of the DNA with BamHI and ClaI and hybridization with a 3Ј env probe yielded a 1.1-kb fragment diagnostic for ecotropic provirus and a 1.9-kb fragment diagnostic for MCF provirus (Fig. 4A) . The 1.9-kb MCF recombinant-specific band could be detected in DNAs from MoϩPyF101 M-MuLV-and M-MuLV-infected tissue that showed MCF recombinant IC titers of Ͼ10 3 per million cells in most cases (Fig. 4B) . Three additional preleukemic MoϩPyF101 M-MuLV i.p.-infected animals (28, 56, and 70 days postinoculation) were tested, and similar results were observed: ecotropic but not polytropic provirus-specific bands were detected, and the numbers of MCF recombinant ICs were less than 1,000/10 6 cells.
MCF recombinants in tumors of Mo؉PyF101 M-MuLV s.c.-inoculated mice.
In previous studies we did not detect MCF recombinants by Southern blot analysis in MoϩPyF101 MMuLV s.c.-infected mice at preleukemic times or in end-stage tumors if they developed (6) . We infected neonatal mice with MoϩPyF101 M-MuLV s.c. and tested them for MCF recombinant and ecotropic ICs at late preleukemic times and in animals that developed tumors (Fig. 3 ). Of 20 animals tested at times from 39 to 148 days, 4 had developed large thymic tumors and other characteristic signs of MoϩPyF101 M-MuLVinduced disease. Of the remaining 16 animals, 12 showed undetectable numbers of MCF recombinant ICs in all tissues. However, three showed very small but detectable numbers of MCF recombinant ICs in one or two tissue compartments (0.2 ϫ 10 6 to 3/10 6 cells) and one showed substantial numbers of MCF recombinant ICs in the thymus (2 ϫ 10 3 /10 6 cells). The MCF recombinant IC results on the preleukemic animals were generally consistent with our previous studies (2) in that the percentage of animals that showed detectable MCF recombinant ICs was much lower following s.c. than i.p. inoculation.
Somewhat unexpectedly, we detected large numbers of MCF ICs in the thymic tumors (5 ϫ 10 2 to 2 ϫ 10 5 /10 6 thymocytes) and in some instances significant numbers in the bone marrow and spleens (7 ϫ 10 4 /10 6 cells) of the four leukemic MoϩPyF101 M-MuLV s.c.-inoculated mice. If MCF recombinant IC numbers and the MCF proviral content in these animals obeyed the same correlation as observed in Fig.  4 , Southern blot analysis would be sensitive enough to detect MCF recombinant proviruses in these tumor DNAs. These four tumors and six additional MoϩPyF101 M-MuLV s.c.-induced tumors from previous experiments were tested for MCF proviruses by Southern blot hybridization (Fig. 5) . The 1.9-kbMCF recombinant-specific BamHI-ClaI fragment was readily detected in 7 of 10 tumor DNAs from mice inoculated s.c. with MoϩPyF101 M-MuLV. A faint 1.9-kb hybridizing band was evident in one additional DNA (Fig. 5, lane 15) , and no MCF provirus-specific band was visualized in two tumor DNAs. However, one of these DNAs (lane 13) was partially degraded in this experiment and was judged MCF recombinant positive in two additional Southern blot assays. In sum, 9 of the 10 tumor DNAs contained MCF proviruses at levels detectable by Southern blot hybridization. Thus, the experiments on MoϩPyF101 s.c.-inoculated animals indicated that MCF recombinant formation and propagation at preleukemic times was substantially reduced or undetectable. Nevertheless, the majority of the animals that developed tumors showed infection by MCF recombinants. For these animals, MCF recombinant formation was correlated with a late step in leukemogenesis.
DISCUSSION
In this study, we investigated MCF recombinant appearance during infection by M-MuLV. MCF recombinant formation in vivo most probably requires two infection events: (i) ecotropic M-MuLV infection of a cell expressing an endogenous replication-defective polytropic MuLV, resulting in the production of heterozygous virions; and (ii) infection of a second cell, in which template switching during reverse transcription leads to formation an integrated replication-competent MCF provirus (5, 9) . The latter cell would produce MCF recombinant virions (or ecotropic-pseudotyped MCF recombinants if it was also infected by M-MuLV). Cells that score as MCF recombinant ICs reflect the second cells involved in MCF recombinant generation or cells that subsequently propagate MCF recombinants. While MCF recombinant IC data cannot distinguish between "generator" and "propagator" cells, in animals where MCF recombinant have not disseminated to all tissues, MCF recombinant ICs will most probably reflect those involved in generation or the earliest stages of propagation.
For mice infected i.p. by M-MuLV, the fact that ecotropic M-MuLV infection established in the bone marrow and spleen more rapidly than in the thymus suggested that MCF recombinant generation might be more likely to occur in these tissues. MCF recombinant ICs first appeared at approximately the same time in all three tissues, i.e., beginning at 13 to 15 days. However, as shown in Table 1 , in discordant animals the bone marrow was included as a site of first appearance of MCF recombinants in virtually every case. This supported the hypothesis that the bone marrow is a likely site of MCF recombinant generation in M-MuLV-infected mice (2) . At the same time, these experiments did not rule out the possibility that MCFs were generated in multiple tissues in the same or different animals. Another conclusion from the M-MuLV i.p.- a Of 34 mice inoculated i.p. with MoϩPyF101 that were examined at times between 16 and 96 days postinoculation, 9 had detectable levels of MCF recombinant ICs in one or two but not all three hematopoietic compartments tested.
b MAb 514-reactive ICs were counted as described in Materials and Methods and the legend to Fig. 3 .
c bdl, below the detection limit (Ͻ0.2 MAb 514-reactive ICs/10 6 cells). d None of the animals examined had MCF recombinant ICs exclusively in the bone marrow.
e None of the animals examined had MCF recombinant ICs exclusively in the spleen.
f An animal with MCF recombinant ICs exclusively in the thymus.
inoculated mice was that once formed, MCF recombinants propagate to higher levels in the thymus, i.e., 1 to 2 log units higher than in bone marrow or spleen. This was consistent with results of previous studies (20) . It was interesting and somewhat surprising that the patterns of initial appearance of MCF recombinants were different for mice inoculated with M-MuLV s.c. vs. i.p. While the plateau levels of MCF recombinant infection were similar for s.c.-and i.p.-infected mice, s.c.-inoculated animals discordant for MCF recombinant infection did not show patterns consistent with generation in the bone marrow. Only 25% of discordant mice showed MCF recombinant ICs in the bone marrow, while 100% showed MCF virus infection in the thymus (Table 2) . Thus, it seems more likely that MCF recombinant generation occurs predominantly in the thymus after s.c. inoculation by M-MuLV.
Studies with MoϩPyF101 M-MuLV provided additional insights into MCF recombinant generation and early propagation. When this virus was injected by the i.p. route, MCF recombinants formed, although with a substantial delay relative to that in wild-type-M-MuLV-infected mice (Fig. 3) . The delay might reflect the fact that in general the viral loads in animals infected i.p. by MoϩPyF101 M-MuLV were somewhat lower than in those infected by wild-type M-MuLV. Amplification of MCF recombinants in the MoϩPyF101 M-MuLV i.p.-infected animals occurred in the thymus at later times, the same as for wild-type-M-MuLV-infected mice. When animals discordant for MCF virus infection were analyzed, the patterns favored generation and initial propagation primarily in the thymus, not in the bone marrow (Table 3) route of inoculation was used. When mice were inoculated with MoϩPyF101 M-MuLV by the s.c. route (where they show attenuated leukemogenicity), very few preleukemic animals showed MCF recombinants even by the sensitive FIA, consistent with results of our previous studies (6) . Another goal of these experiments was to test the hypothesis that MCF recombinants are important for early (preleukemic) events in M-MuLV leukemogenesis. We previously suggested that MCF recombinants are involved in preleukemic M-MuLVinduced events such as splenic hyperplasia, bone marrow hematopoietic defects, and accelerated thymic atrophy (15) . The detailed analyses carried out here indicate that this hypothesis is unlikely to be correct. While MCF recombinants first appeared in M-MuLV-infected mice well before the preleukemic events (13 to 15 days), the levels of infection were low, i.e., plateau levels of 10 3 to 10 4 ICs per 10 6 cells (0.1 to 1% MCF recombinant infection) in the bone marrow and spleen. Thus, in these tissues that were undergoing substantial preleukemic changes, most of the cells were not infected by MCF recombinants. The lack of a role for MCF recombinants in M-MuLVinduced preleukemic changes was further substantiated by the studies on mice infected by MoϩPyF101 M-MuLV. atrophy showed no detectable MCF recombinants in the thymus (3). A similar lack of correlation between MCF recombinants and induction of splenomegaly (erythroid hyperplasia) induced by Friend MuLV has been reported (30) . However, in the experiments described here, only the nonadherent cells from the spleen and thymus were analyzed. If MCF recombinant infection of adherent (stromal) elements led to preleukemic changes, this might have escaped detection. On the other hand, for the bone marrow, all of the cells (including stromal cells) were analyzed, but it is still possible that MCF virus infection of a minority subset of cells in the bone marrow is important.
At the same time, these experiments provide strong support for a role of MCF recombinants in later steps in leukemogenesis. In particular, in mice inoculated with MoϩPyF101 MMuLV by the s.c. route, the great majority that did not have tumors had undetectable or extremely small numbers of MCF recombinant ICs. Nevertheless, most of the tumors in the individuals that developed leukemia were MCF virus infected. Thus, for these animals, there was a strong selection for MCF recombinants in the tumors. The appearance of MCFs may have been the final rate-limiting event for disease development. The overall reduced rate of leukemogenesis by MoϩPyF101 M-MuLV after s.c. inoculation may have resulted from both the low levels of MCF recombinants formed and a lower level of ecotropic virus load (compare Fig. 3 with Fig. 2 ).
As mentioned in Results, we previously did not detect MCF recombinants in MoϩPyF101 M-MuLV s.c.-infected tumors by Southern blot analysis (6) , whereas in the present experiments we did. This was probably due to the restriction endonucleases used. Previously, a BamHI-XbaI digest was used to test for a 2.3-kb MCF virus-diagnostic fragment that hybridized to an MCF virus env-specific probe (6). The diagnostic fragment was only slightly smaller than restriction fragments corresponding to endogenous MuLV proviruses in NIH Swiss mice. In retrospect, two classes of LTR changes could have resulted in failure to detect the MCF virus-diagnostic BamHIXbaI fragment. Multimerization of M-MuLV enhancer sequences in the MoϩPyF101 M-MuLV LTR could result in comigration of the diagnostic MCF virus fragment with an endogenous MuLV-related fragment. Alternatively, deletion of polyomavirus enhancer sequences and the adjacent XbaI site could have converted the MCF virus-diagnostic fragment to viral-cellular junction fragments of indeterminate size. In subsequent studies, we observed both classes of LTR alterations (2, 4). The BamHI-ClaI restriction digestion used in these experiments is not influenced by alterations in the MoϩPyF101 M-MuLV LTR. Indeed, several of the previously isolated tumor samples illustrated in Fig. 5 that showed the MCF virus-diagnostic 1.9-kb BamHI-ClaI fragment had been previously classified as MCF virus negative on the basis of the BamHI-XbaI digest (6). Additional Southern blot digestions confirmed that the MoϩPyF101 M-MuLV s.c.-induced tumors had LTR rearrangements consisting of either or deletions or expansions of the enhancer sequences (results not shown).
In summary, several conclusions resulted from these studies. First, both the route of inoculation and the nature of the enhancers appeared to affect the sites of MCF recombinant generation and/or early propagation in M-MuLV-infected mice. Second, the initial site(s) of MCF recombinant appearance does not appear to affect the efficiency of leukemogenesis. Third, MCF recombinants do not appear to be involved in establishing M-MuLV-induced preleukemic changes. Finally, MCF recombinants are more likely to be involved in late steps in leukemogenesis such as activation of proto-oncogenes, induction of cytokine autocrine loops, and activation of tumor progression genes (15, 16) .
